首页|丹参-红花配伍抗脑缺血再灌注损伤的机制研究进展

丹参-红花配伍抗脑缺血再灌注损伤的机制研究进展

扫码查看
脑缺血再灌注损伤(cerebral ischemia reperfusion injury,CIRI)是指当脑缺血一定时间再恢复血液供应后,其功能未恢复,反而导致更加严重的脑功能障碍.CIRI是缺血性脑卒中的共同特征和病理生理机制,其主要通过脑神经元兴奋性氨基酸毒性增强、氧自由基损伤、钙超载、炎症反应以及细胞凋亡等途径造成神经细胞损伤.当前,现代医学防治CIRI的重要手段是静脉溶栓.然而,CIRI具有发病急、治疗时间窗短、预后差的特点,治疗手段具有局限性.中药丹参-红花配伍具有抗CIRI的作用,临床疗效较好;其作用机制可能是促进血管新生、抗细胞凋亡等效应.本综述以血管稳态为切入点,总结了中药丹参-红花配伍抗CIRI的生物学机制,为后续相关实验及临床研究提供一定的理论依据.
Research Progress on Mechanism of the Combination of Salvia Miltiorrhiza and Safflower Against Cerebral Ischemia-reperfusion Injury
Cerebral ischemia reperfusion injury(CIRI)refers to the inability to restore blood supply after a cer-tain period of cerebral ischemia,leading to more severe brain dysfunction.CIRI is a common feature and patho-physiological mechanism of ischemic stroke,which mainly causes neuronal damage through pathways such as increased excitatory amino acid toxicity in brain neurons,oxygen free radical damage,calcium overload,inflam-matory response,and cell apoptosis.The latest research suggests that CIRI's prevention and treatment metholo-gy is intravenous thrombolysis.However,CIRI is characterized by short treatment time windows and unfavorable prognosis due to the limitation.The combination of traditional Chinese medicine salvia miltiorrhizo and safflower has the effect of anti-CIRI,and good clinical efficacy.Its mechanism may be revalent to promote angiogenesis,anti-apoptosis and other effects.Taking vascular homeostasis as the starting key point,the paper discusses the biological mechanism of the combination of traditional Chinese medicine salvia miltiorrhizo and safflower in treating CIRI,providing a certain theoretical basis for subsequent related experiments and clinical studies.

salvia miltiorrhizosafflowercombinationcerebral ischemia reperfusion injurymechanismvascu-lar homeostasis

李文武、徐青云、雷烨、苗琦、张怡敏、朱慧渊

展开 >

陕西中医药大学,咸阳 712046

丹参 红花 配伍 脑缺血再灌注损伤 作用机制 血管稳态

国家自然科学基金陕西中医药大学第二附属医院糖尿病血管病变中西医结合治疗研究创新团队研究项目

821742682020XKTD-C01

2024

宁夏医科大学学报
宁夏医科大学

宁夏医科大学学报

CSTPCD
影响因子:0.84
ISSN:1674-6309
年,卷(期):2024.46(3)
  • 73